The Journal of Clinical Pharmacology · 1982 · 33 citations · 14 references
PharmacyPharmacokineticsPharmacologyBioavailabilityDrug MetabolismRenal PharmacokineticsBioavailability AnalysisDrug DispositionPhysicochemical Determinants Of BioavailabilityRenal Drug AbsorptionRenal Drug DistributionRenal PharmacologyRenal BioavailabilitySpironolactone TherapyTablets
The bioavailability and pharmacologic activity of tablets containing micronized spironolactone chemical (median particle size 2.21 micrometers) were compared to those of tablets made from standard spironolactone chemical (median particle size 78.8 micrometers) in healthy men. Apart from particle size, all features of these tablets were identical. After 200-mg single doses, the bioavailability of micronized tablets was significantly higher than that of standard tablets. Furthermore, as assessed by 24-hour urine log10 10 Na/K ratio, the pharmacologic activity of micronized spironolactone was significantly greater than that of the standard formulation. The significant influence on renal antimineralocorticoid activity of raised plasma and urinary levels of canrenone, quantitatively the major active metabolite of spironolactone in man, emphasizes the clinical importance of the bioavailability of spironolactone preparations. Since this study, the process used in the manufacture of spironolactone (Aldactone) tablets has been under review.
14
Biopharmaceutics and Relevant Pharmacokinetics
John G. Wagne · Drug Information Bulletin · 1970 · 618 citations
A E HUGH, J A FOX · The Lancet · 1963 · 260 citations
Spironolactone. I. Disposition and metabolism
Aziz Karim, J. Zagarella, Jeremy D. Hribar et al. · Clinical Pharmacology & Therapeutics · 1976 · 83 citations